Similar articles

• Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

  Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B. Strumberg D, et al. Oncologist. 2007 Apr;12(4):426-37. doi: 10.1634/theoncologist.12-4-426. Oncologist. 2007. PMID: 17470685 Review.
• Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

  Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Abou-Alfa GK, et al. J Clin Oncol. 2006 Sep 10;24(26):4293-300. doi: 10.1200/JCO.2005.01.3441. Epub 2006 Aug 14. J Clin Oncol. 2006. PMID: 16908937 Clinical Trial.
• Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.

  Hilger RA, Richly H, Grubert M, Kredtke S, Thyssen D, Eberhardt W, Hense J, Schuler M, Scheulen ME. Hilger RA, et al. Int J Clin Pharmacol Ther. 2009 Jan;47(1):61-4. doi: 10.5414/cpp47061. Int J Clin Pharmacol Ther. 2009. PMID: 19203541 No abstract available.
• Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.

  Moncrieff M, Shannon K, Hong A, Hersey P, Thompson J. Moncrieff M, et al. Melanoma Res. 2008 Apr;18(2):161-2. doi: 10.1097/CMR.0b013e3282f3d117. Melanoma Res. 2008. PMID: 18337654
• Sorafenib: a clinical and pharmacologic review.

  Iyer R, Fetterly G, Lugade A, Thanavala Y. Iyer R, et al. Expert Opin Pharmacother. 2010 Aug;11(11):1943-55. doi: 10.1517/14656566.2010.496453. Expert Opin Pharmacother. 2010. PMID: 20586710 Review.